Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANDA Backlog: FDA Climbs The Mountain, Will Need To Climb It Again

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency has acted on 84% of generic applications pending when user fee program launched, but most actions were 'complete response' letters, which do not reduce review workload.

You may also be interested in...



First Generic Approvals Decline For Fourth Straight Year At US FDA

Blemish in otherwise record-setting performance could simply be a result of coalescing variables, but it robs the agency of an easy pricing message.

First Generic Approvals Decline For Fourth Straight Year At US FDA

Blemish in otherwise record-setting performance could simply be a result of coalescing variables, but it robs the agency of an easy pricing message.

ANDA Withdrawals Increase Faster Than Approvals

FY 2016 figure, the highest seen by US FDA under the generic drug user fee program, could be the result of older applications exiting the queue, and may be a sign of progress in dealing with the review backlog.

Related Content

Topics

UsernamePublicRestriction

Register

PS079310

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel